Iveric's Trial Progress And Other News: The Good, Bad And Ugly Of Biopharma [Seeking Alpha]
Rubius Therapeutics, Inc. (RUBY)
Last rubius therapeutics, inc. earnings: 3/12 07:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
SummaryIveric Bio commences second pivotal trial.Rubius offers data for RTX-240.Zynerba flunks Fragile X Syndrome trial.Iveric Bio Goes Ahead with Second Pivotal Phase 3 Study of ZimuraIveric Bio (ISEEannouncedGATHER2 trial is expected to recruit nearly 400 patients. These participants will be randomized to receive either monthly administration of Zimura 2 mg or sham during the first 12 months of the trial. At that point of time, a primary efficacy analysis of the mean rate of change of GA growth at 12 months is scheduled to be performed. Kourous A. Rezaei, M.D., Chief Medical Officer of IVERIC bio said, “We have experienced impressive enthusiasm by our investigators to initiate the second Phase 3 trial, GATHER2, based on the robustness of efficacy, the strength of the statistical evidence, and the favorable safety profile of Zimura in the GATHER1 Phase 3 trial.” The company also stated that potentially GATHER1 is the only Phase 3 clinical trial demonstrating early inhibition of GA gr
Show less
Read more
Impact Snapshot
Event Time:
RUBY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RUBY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RUBY alerts
High impacting Rubius Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics